• Profile
Close

Long-term safety of growth hormone – A combined registry analysis

Clinical Endocrinology Oct 26, 2017

Stochholm K, et al. - Published safety data, focusing on mortality, neoplasms, cerebrovascular events and diabetes across a number of large-scale pharmaceutical company growth hormone (GH) registries was assessed in this study. The authors revealed that patients with risk factors for malignancy or type 2 diabetes needed to be treated with caution and monitored during follow-up. However, current published data provided reassurance on the long-term safety profile of GH in patients receiving GH treatment.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay